One of today's notable stocks in decline is AMAG Pharmaceuticals (NASDAQ:AMAG), down 2.1% to $15.93. The S&P is trading lower by 0.7% to 1,503 and the Dow is trading 0.8% lower to 13,900.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
In the past 52 weeks, shares of AMAG Pharmaceuticals have traded between a low of $12.43 and a high of $18.50 and are now at $15.93, which is 28% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.9% while the 200-day MA has remained constant.
Potential upside of 4.6% exists for AMAG Pharmaceuticals, based on a current level of $15.93 and analysts' average consensus price target of $16.67. The stock should find initial support at its 200-day moving average (MA) of $15.44 and further support at its 50-day MA of $15.28.